Community Advisory Board
Hepatitis B and D Global Community Advisory Board (CAB)
The mission of the CAB is to integrate community perspectives and expertise into hepatitis B and D drug development, as well as public health and clinical research, to ensure that the voices of those living with and affected by hepatitis B and D are represented, and to drive progress toward a hepatitis B cure and effective hepatitis D therapeutics. The HBV CAB is an all-volunteer group composed of 12-15 people living with and affected by CHB who provide individual expertise to inform hepatitis B drug and clinical trial development. HBV-CAB members serve 24-month terms.Goals/Objectives
- Provide training and education to facilitate increased community engagement in and awareness of hepatitis B and D drug development, public health research, and programming clinical trials
- Establish and maintain opportunities for community members to interact with researchers and other key stakeholders and provide their input/recommendations on topics such as drug development and clinical trials, treatment guidelines, and hepatitis B and D diagnostics.
- Promote diverse and inclusive representation of communities highly affected by hepatitis B and D in drug development, public health research and programming, and clinical research
| Anthony Atuhaire, Uganda | Silvana Lesidrenska, Bulgaria |
| Bright Ansah, United States | Baasansuren Lkhagvasuren, Mongolia |
| Joe Balestreri, United States | Wendy Lo, United States |
| Jacki Chen, Unites States/Taiwan | Partizan Malkaj, Albania |
| Dan-Andrei Cretu, Romania | Chris Munoz, Philippines |
| George Sebastian Gherlan, Romania | Richard Njouom, Cameroon |
| Susan Amanda Goldring, United Kingdom | Prince Ochuko Okinedo, Nigeria |
| Ibrahima Gueye, Senegal | Danielle Raphael, Israel |
| Melissa Hsu, United States | Lori Scott, United States |
| Shaibu Issa, Tanzania | Lien Tran, Australia |
| Kenneth Kabagambe, Uganda | Thomas Tu, Australia |
| Philip Kwame Yeboah, Ghana |